Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 9.6% over the past three years. Valuation Update With 7 Day Price Move • May 20
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to NT$25.00, the stock trades at a trailing P/E ratio of 52.3x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 19% over the past three years. New Risk • May 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 32% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Market cap is less than US$100m (NT$1.48b market cap, or US$46.9m). Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to NT$16.60, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 15% over the past three years. Duyuru • Apr 02
MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026 MicroBase Technology Corp., Annual General Meeting, Jun 25, 2026. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 38% After last week's 38% share price gain to NT$19.70, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.9% over the past three years. Valuation Update With 7 Day Price Move • Mar 16
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to NT$14.05, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years. New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$788.4m market cap, or US$25.1m). New Risk • Feb 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$750.6m market cap, or US$23.9m). Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to NT$11.85, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 34% over the past three years. New Risk • Aug 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$842.9m market cap, or US$28.2m). Reported Earnings • Apr 26
Full year 2024 earnings released: EPS: NT$0.86 (vs NT$0.47 in FY 2023) Full year 2024 results: EPS: NT$0.86 (up from NT$0.47 in FY 2023). Revenue: NT$214.8m (up 10% from FY 2023). Net income: NT$69.4m (up 82% from FY 2023). Profit margin: 32% (up from 20% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$10.45, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 19x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 17% over the past three years. Buy Or Sell Opportunity • Apr 14
Now 21% overvalued Over the last 90 days, the stock has fallen 17% to NT$10.15. The fair value is estimated to be NT$8.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable. Duyuru • Apr 02
MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025 MicroBase Technology Corp., Annual General Meeting, Jun 26, 2025. Location: no,756, ch`ieh tung rd., bade district, taoyuan city Taiwan Buy Or Sell Opportunity • Mar 28
Now 22% overvalued Over the last 90 days, the stock has fallen 23% to NT$10.40. The fair value is estimated to be NT$8.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.3% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Feb 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$951.3m market cap, or US$28.9m). New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (NT$1.12b market cap, or US$34.3m). Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$13.85, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 5.1% over the past three years. Reported Earnings • Apr 12
Full year 2023 earnings released: EPS: NT$0.48 (vs NT$0.079 in FY 2022) Full year 2023 results: EPS: NT$0.48 (up from NT$0.079 in FY 2022). Revenue: NT$194.8m (up 6.8% from FY 2022). Net income: NT$38.1m (up 500% from FY 2022). Profit margin: 20% (up from 3.5% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Apr 03
MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024 MicroBase Technology Corp., Annual General Meeting, Jun 24, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (NT$1.01b market cap, or US$31.8m). New Risk • Aug 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.9% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.12b market cap, or US$35.3m). Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: NT$0.08 (vs NT$0.47 loss in FY 2021) Full year 2022 results: EPS: NT$0.08 (up from NT$0.47 loss in FY 2021). Revenue: NT$182.3m (down 14% from FY 2021). Net income: NT$6.35m (up NT$43.7m from FY 2021). Profit margin: 3.5% (up from net loss in FY 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 15
First half 2022 earnings released: NT$0.03 loss per share (vs NT$0.11 loss in 1H 2021) First half 2022 results: NT$0.03 loss per share (up from NT$0.11 loss in 1H 2021). Revenue: NT$82.9m (down 26% from 1H 2021). Net loss: NT$2.17m (loss narrowed 75% from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 13% per year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 18
First half 2021 earnings released: NT$0.11 loss per share (vs NT$0.41 loss in 1H 2020) The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: NT$111.6m (down 9.0% from 1H 2020). Net loss: NT$8.84m (loss narrowed 71% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 11
Full year 2020 earnings released: NT$0.95 loss per share (vs NT$0.75 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: NT$249.8m (down 5.9% from FY 2019). Net loss: NT$74.0m (loss widened 51% from FY 2019). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 01
New 90-day low: NT$12.75 The company is down 34% from its price of NT$19.45 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 26% over the same period. Is New 90 Day High Low • Jan 15
New 90-day low: NT$14.70 The company is down 25% from its price of NT$19.50 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: NT$16.20 The company is down 16% from its price of NT$19.40 on 24 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 13% over the same period. Is New 90 Day High Low • Dec 05
New 90-day low: NT$17.45 The company is down 9.0% from its price of NT$19.10 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 06
New 90-day low: NT$18.90 The company is down 8.0% from its price of NT$20.55 on 07 August 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is down 4.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: NT$19.00 The company is down 7.0% from its price of NT$20.50 on 24 June 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 2.0% over the same period.